Celldex Therapeutics is the first antibody-based combination immunotherapy company. Its drug candidate pipeline for treating cancer and other difficult-to-treat diseases is based on its antibody-focused Precision Targeted Immunotherapy (PTI) Platform, which is a complementary portfolio of monoclonal antibodies, antibody-targeted therapeutics and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, visit the company’s Web site: http://www.celldextherapeutics.com
Let us hear your thoughts below: